The first plant allergen to be cloned—the story of the major birch pollen allergen Bet v 1
Allergy · 2024
DOI: 10.1111/all.16066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Heimo Breiteneder. Beteiligte Einrichtung: Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Allergens, Betula. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
In 1976, Dietrich Kraft1 became head of the newly established Allergy and Immunology Research Group at the Department of General and Experimental Pathology of the Medical Faculty of the University of Vienna, which became the Medical University of Vienna in 2004. While working in a Viennese allergy outpatient clinic, Kraft concluded that allergy test and allergen immunotherapy solutions could only be standardized on the basis of pure recombinant allergens. Kraft developed this idea further during an extended hospital stay after a serious bicycle accident. On December 12, 1983, in a 1-h telephone conversation, he convinced Michael Breitenbach to contribute his expertise in molecular cloning to this project. Otto Scheiner and Helmut Rumpold contributed expertise in immunohistochemistry and medical laboratory techniques. This laid the foundation for the establishment of the Vienna School of Molecular Allergology. In the years 1983–1984, investments in cloning and the production of recombinant allergens were of no interest either to Austrian funding agencies or pharmaceutical companies active in the field of allergy. At a banquet of the Austrian Society of Allergology and Immunology, Kraft explained his vision of recombinant allergens to Jörg Mayrhofer who saw a business opportunity and agreed to finance Kraft's ambitious plans. The company Biomay was founded in 1984 to fund the formative years of Kraft's molecular allergology team. As around 5% of the Austrian population suffer from birch pollinosis and birch pollen contains only one major allergen, this allergen was selected as target. This allergen was named Bet v 1, based on the then current name for white birch (Betula verrucosa), following the official guidelines of allergen nomenclature.2 Breitenbach recruited Heimo Breiteneder to clone the Bet v 1 cDNA, and work began on May 2, 1985. mRNA was first isolated from various tissues, including roots of birch seedlings, leaves, inflorescences, and finally birch pollen. Translated into proteins in the wheat germ system, IgE-binding from sera of birch pollen allergic individuals to a 17 kDa protein, presumably Bet v 1, was observed.3 Consequently, the E. coli phage λgt11 was selected to produce a cDNA expression library from birch pollen mRNA. The expression library was screened with sera from birch pollen allergics, a technique that had not been used before. Phage λgt11 clones containing Bet v 1-encoding cDNAs and thus producing recombinant Bet v 1 in infected E. coli cells were identified on July 3, 1988. The complete cDNA sequence of Bet v 1 was published in 19894 as the world's first cloned plant allergen. Radauer et al.5 searched the Protein Data Bank for Bet v 1 structural homologs and discovered the occurrence of members of the Bet v 1 superfamily in all three kingdoms of life, archaea, bacteria, and eukaryotes (Figure 1). Today, the so-called Bet_v_1_like set encompasses 29 families (https://www.ebi.ac.uk/interpro/set/pfam/CL0209/; accessed October 2023). The vast majority of allergens are found in the PR-10 subfamily of the Bet v 1 family illustrating clinically observed cross-reactivities at the molecular level. Since 1989, the Vienna School of Molecular Allergology has discovered numerous allergens that are used as recombinant proteins in various diagnostic tests. The allergen arrays pioneered by Rudolf Valenta are now routinely used to define sensitization profiles and develop personalized treatment and prevention strategies for allergies.6 Recombinant DNA technology has enabled the production of hypoallergenic folding variants, T cell epitope containing peptides, carrier bound B cell epitope-containing peptides, and virus-like particle-coupled allergens for immunotherapy all based on allergen encoding sequences and experimentally determined allergen structures.7 From its beginnings to this day, the discipline of molecular allergology has made amazing progress. The official allergen nomenclature website (https://allergen.org/) presently lists 1109 allergens. The Molecular Allergology User's Guide 2.0, published by the EAACI (free download at https://eaaci-cdn-vod02-prod.azureedge.net/KnowledgeHub/education/books/MAUG_2_20221214_EBOOK.pdf), summarizes the current state of knowledge about the physicochemical and biological properties of allergenic proteins, their sources and nomenclature, and their use as diagnostic reagents in clinical practice. This article did not receive any funding. The author declares no conflict of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Heimo Breiteneder
Zitieren
APA
Breiteneder, H. (2024). The first plant allergen to be cloned—the story of the major birch pollen allergen Bet v 1. Allergy. https://doi.org/10.1111/all.16066
Vancouver
Breiteneder H. The first plant allergen to be cloned—the story of the major birch pollen allergen Bet v 1. Allergy. 2024. doi:10.1111/all.16066
BibTeX
@article{Breiteneder2024,
author = {Breiteneder, Heimo},
title = {The first plant allergen to be cloned—the story of the major birch pollen allergen Bet v 1},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.16066}
}
EUVIMED